Search Results
Results found for "Remi Janicot"
- Exploring the Breakthroughs in GPCR Research
This week's highlight includes congrats to: Remi Janicot, and Dr.
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
🎇 This Week’s Highlights: Congrats to: Remi Janicot , and Mikel Garcia-Marcos for their excellent
- 📰 GPCR Weekly News, March 11 to 17, 2024
Georgios Skiniotis, et al. for their research on Time-resolved cryo-EM of G-protein activation by a GPCR Remi Janicot, Alex Luebbers, Mikel Garcia-Marcos, et al. for their work on Direct interrogation of context-dependent
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
Janicot, R., et al., Direct interrogation of context-dependent GPCR activity with a universal biosensor
- Unlock the Hidden Lives of Receptors – Are You Ready?
What if the static models we've relied on for decades have been hiding the truth?
- What If Your Data is Lying to You? The Calcium Assay Dilemma
You’ll learn why calcium signals are inherently transient—giving rise to a “hemi-equilibrium” window
- Antibodies That Don’t Block, They Activate: A New Angle on Autoimmunity and GPCRs
or treatment research based on GPCR targets Beyond Classic ELISAs Traditional autoantibody testing relies
- Curve Shifts Don’t Lie, But Your Eyes Might
The first trap in drug discovery is relying on visual inspection. Scatter can masquerade as signal. Instead of relying on debate—or worse, intuition—you can calculate an F-value that objectively shows
- How Advanced GPCR Kinetics Sharpen Decision Making (and Save You Time)
to confirm equilibrium the right way, detect time-dependent occupancy and complex activity, leverage hemi-equilibrium Protect your screening funnel: Use hemi-equilibrium readouts to flag artifacts before they inflate your
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
Get a preview of Terry’s teaching style and see why drug hunters worldwide rely on his frameworks. Here, you’ll get: Weekly lectures that sharpen the exact tools you rely on in discovery.
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
regulates β-arrestin recruitment across glucagon family receptors, revealing that GLP-1R and GIPR rely
- Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1
The reported ACKR1 expression by macrophages in Hur et al. relied on using commercial anti-ACKR1 antibody
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
Homology modeling relies on using the known structure of a homologous protein as a template to model
- Regulation of rod photoreceptor function by farnesylated G-protein γ-subunits
amino acid identity, and identical posttranslational farnesylation of their Gγ subunits, rods and cones rely
- How Fast Does a Drug Work?
Yet most discovery teams still rely on classic affinity metrics alone, often overlooking how kinetic
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
With Premium, you move faster, smarter, and more confidently than peers relying on scattered signals.
- Radioligands vs. Fluorescent Ligands: Binding Assays
Traditional radioligand protocols rely on filtration assay or on scintillation proximity technologies
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
The stakes are too high to rely on assumptions.
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
GPCR Allosteric Thinking Changes the Game in Drug Discovery For decades, drug discovery pipelines have relied
- Innovative Data-Driven Solutions: The pHSense Revolution
From Bench to Breakthrough: Why pHSense Matters Decades of GPCR research have relied heavily on engineered
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
Premium Members rely on this intelligence weekly—and here’s your curated preview.
- How to Use Statistical Methods to Strengthen Every GPCR Drug Discovery Decision
Avoid wasted resources: Stop relying on “n=3” by default.
- GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already
- The Truth About GPCR Product Launches: Years in the Making
cAMP assay, Trinquet’s team took a risky bet: develop a functional readout for Gq signaling without relying
- The Five Traps of Ignoring Kinetics
The Hemi-Equilibrium Problem Calcium assays look simple.
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
The company’s scientific approach relied on targeting GPCRs — specifically opioid receptors — using biased
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
The future According to the authors, the future of AI relies in 6 main areas: 1. Greater application of unsupervised machine learning: most applications of ML in GPCR drug discovery have relied
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
Yet too many programs rely solely on affinity metrics—Kd—as proxies for in vivo behavior, missing a critical
- From Snapshots to Predictions: Why Mechanism of Action Matters
Determining Mechanism of Action: Your Edge If you’re still relying on descriptive observations—“looks
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
From Bench Frustrations to Breakthrough Design For decades, GPCR trafficking research relied on overexpression
























